Global Soft Tissue Sarcoma Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

October 2017 | 220 pages | ID: GA4179474CCEN
Precision Business Insights (PBI)

Abstracts

Global Soft Tissue Sarcoma Treatment Market:

Global soft tissue sarcoma treatment market estimated to be valued US$ XX Mn in 2017 and poised to grow at CAGR of XX% over 2017-2023. Market for soft tissue sarcoma treatment projected to reach US$ XX Mn by 2023.

Soft tissue sarcoma is the rare and diverse group of cancers that develop from soft tissues such as blood vessels, muscles, fats, nerves, and deep skin tissues etc. There are around 50 different types of soft tissue sarcoma have been identified, the common types of soft tissue sarcoma are liposarcomas which develop from fat cells, and leiomyosarcomas, which arise from smooth muscle tissue. The soft tissue sarcoma can be treated by the combined chemotherapy, radiotherapy, and surgery to remove the tumour. If surgical procedure is not required, chemotherapy alone can be used.

Increase in the prevalence and incidence of different types of cancers, rise in the number of soft tissue sarcoma cases, increase in the R&D activities on drugs and other biological therapies, patent expiry of branded drugs, increase in the healthcare expenditure and rise in quality patient care are expected to fuel the soft tissue sarcoma treatment market over the forecast period. However, high cost for the radiotherapy and chemotherapy, stringent regulatory guidelines, and adverse effects associated with the treatment might hinder the growth of soft tissue sarcoma treatment market over the forecast timeframe.

The soft tissue sarcoma treatment market has been segmented on basis of disease type, treatment type, and end user

Based on the treatment type, soft tissue sarcoma treatment market is segmented into following:

• Targeted Therapy
• Chemotherapy
• Anti-angiogenesis drugs
• Radiation Therapy
• Internal Radiation Therapy
• External Radiation Therapy

Based on the disease type, soft tissue sarcoma treatment market is segmented into following:

• Local Sarcoma
• Regional Sarcoma
• Metastatic Sarcoma

Based on the distribution channel, soft tissue sarcoma treatment market is segmented into following:

• Hospitals
• Oncology Clinics
• Long Term Care Centres

Soft tissue sarcoma treatment market is in growing stage as very fewer products in the market are currently approved to treat various types of soft tissue sarcoma. Various international companies are very active in the soft tissue sarcoma treatment market in terms of product launches, research, and development activities. For instance, in 2012, Threshold Pharmaceuticals Inc. signed a global license and co-development agreement for Evofosfamide, which is the most advanced first-line drug for soft tissue sarcoma with Merck KGaA. Merck KGaA paid US$ 110 Mn as upfront payment and milestone payments to Threshold, and additionally, Merck KGaA covers 70% of all evofosfamide development expenses. GSK’s Votrient (pazopanib) is approved for second-line treatment, and another drug Aldoxorubicin is approved as first-line drug for the treatment of soft tissue sarcoma. Currently, doxorubicin is commonly used for the treatment of soft tissue sarcoma.

Geographically, soft tissue sarcoma treatment market segmented into following regions Viz. North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America may lead the soft tissue sarcoma treatment market owing to increase in the prevalence of the disease. According to American Cancer Society, approximately 12,390 people in 2016 are suffering soft tissue sarcoma and cancer. Europe holds a key share in soft tissue sarcoma treatment market attributed to change in lifestyle, increase in R&D activities for the development of new drugs. Asia-Pacific region accounts for a significant growth due to increase in cancer cases, and rise in awareness about advanced soft tissue sarcoma treatment.

Some of the players in the soft tissue sarcoma treatment market are GlaxoSmithKline plc (U.K.), Eli Lilly and Company (U.S.), Pfizer, Inc. (U.S.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), and Celgene Corporation (U.S.) to name a few.

In October 2016, U.S. Food and Drug Administration issued an accelerated approval notice for Eli Lilly and Company’s drug Lartruvo (Olaratumab) with Doxorubicin to treat certain types soft tissue carcinoma

REPORT OUTLINE:

• The report provides granular level information about the market size, regional market share and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
• The Report Outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments and startup’s details that are working in the industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL SOFT TISSUE SARCOMA TREATMENT MARKET INTRODUCTION

2.1. Global Soft Tissue Sarcoma Treatment Market – Taxonomy
2.2. Global Soft Tissue Sarcoma Treatment Market –Definitions
  2.2.1. Treatment Type
  2.2.2. Distribution Channel

3. GLOBAL SOFT TISSUE SARCOMA TREATMENT MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Soft Tissue Sarcoma Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Soft Tissue Sarcoma Treatment Market – Regulations
  3.6.1. U.S
  3.6.2. Europe
  3.6.3. Japan
3.7. Global Soft Tissue Sarcoma Treatment Market – Recent Treatment Launches

4. GLOBAL SOFT TISSUE SARCOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL SOFT TISSUE SARCOMA TREATMENT MARKET, BY TREATMENT TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Targeted Therapy
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. Chemotherapy
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis
5.3. Anti-angiogenesis Drugs
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis
5.4. Radiation Therapy (Internal Radiation Therapy and External Radiation Therapy)
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.4.3. Market Opportunity Analysis

6. GLOBAL SOFT TISSUE SARCOMA TREATMENT MARKET, BY DISEASE TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Local Sarcoma
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Regional Sarcoma
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. Metastatic Sarcoma
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis

7. GLOBAL SOFT TISSUE SARCOMA TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Hospital Pharmacies
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Long-Term Care Centers
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis

8. GLOBAL SOFT TISSUE SARCOMA TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.1.3. Market Opportunity Analysis
8.2. Europe
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.3.3. Market Opportunity Analysis
8.4. Latin America
  8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
  8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.5.3. Market Opportunity Analysis
8.6. Global Soft Tissue Sarcoma Treatment Market - Opportunity Analysis Index - By Treatment Type, By Disease Type, By Distribution Channel, and Region, 2017 – 2023

9. NORTH AMERICA SOFT TISSUE SARCOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  9.1.1. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    9.1.1.1. Targeted Therapy
    9.1.1.2. Chemotherapy
    9.1.1.3. Anti-angiogenesis drugs
    9.1.1.4. Radiation Therapy
      9.1.1.4.1. Internal Radiation Therapy
      9.1.1.4.2. External Radiation Therapy
  9.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.2.1. Local Sarcoma
    9.1.2.2. Regional Sarcoma
    9.1.2.3. Metastatic Sarcoma
  9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.3.1. Hospital Pharmacies
    9.1.3.2. Retail Pharmacies
    9.1.3.3. Long-Term Care Centers
  9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    9.1.4.1. U.S.
    9.1.4.2. Canada
  9.1.5. North America Soft Tissue Sarcoma Treatment Market - Opportunity Analysis Index - By Treatment Type, By Disease Type, By Distribution Channel, and Country, 2017 – 2023
  9.1.6. North America Soft Tissue Sarcoma Treatment Market Dynamics – Trends

10. EUROPE SOFT TISSUE SARCOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  10.1.1. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    10.1.1.1. Targeted Therapy
    10.1.1.2. Chemotherapy
    10.1.1.3. Anti-angiogenesis drugs
    10.1.1.4. Radiation Therapy
      10.1.1.4.1. Internal Radiation Therapy
      10.1.1.4.2. External Radiation Therapy
  10.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.2.1. Local Sarcoma
    10.1.2.2. Regional Sarcoma
    10.1.2.3. Metastatic Sarcoma
  10.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.3.1. Hospital Pharmacies
    10.1.3.2. Retail Pharmacies
    10.1.3.3. Long-Term Care Centers
  10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.4.1. Germany
    10.1.4.2. UK
    10.1.4.3. France
    10.1.4.4. Spain
    10.1.4.5. Italy
    10.1.4.6. Russia
    10.1.4.7. Poland
    10.1.4.8. Rest of Europe
  10.1.5. Europe Soft Tissue Sarcoma Treatment Market - Opportunity Analysis Index - By Treatment Type, By Disease Type, By Distribution Channel, and Country, 2017 – 2023
  10.1.6. Europe Soft Tissue Sarcoma Treatment Market Dynamics – Trends

11. ASIA-PACIFIC SOFT TISSUE SARCOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  11.1.1. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    11.1.1.1. Targeted Therapy
    11.1.1.2. Chemotherapy
    11.1.1.3. Anti-angiogenesis drugs
    11.1.1.4. Radiation Therapy
      11.1.1.4.1. Internal Radiation Therapy
      11.1.1.4.2. External Radiation Therapy
  11.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.2.1. Local Sarcoma
    11.1.2.2. Regional Sarcoma
    11.1.2.3. Metastatic Sarcoma
  11.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.3.1. Hospital Pharmacies
    11.1.3.2. Retail Pharmacies
    11.1.3.3. Long-Term Care Centers
  11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
    11.1.4.1. Japan
    11.1.4.2. China
    11.1.4.3. India
    11.1.4.4. ASEAN
    11.1.4.5. Australia & New Zealand
    11.1.4.6. Rest of Asia-Pacific
  11.1.5. Asia-Pacific Soft Tissue Sarcoma Treatment Market - Opportunity Analysis Index - By Treatment Type, By Disease Type, By Distribution Channel, and Country, 2017 – 2023
  11.1.6. Asia-Pacific Soft Tissue Sarcoma Treatment Market Dynamics – Trends

12. LATIN AMERICA SOFT TISSUE SARCOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  12.1.1. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.1.1.1. Targeted Therapy
    12.1.1.2. Chemotherapy
    12.1.1.3. Anti-angiogenesis drugs
    12.1.1.4. Radiation Therapy
      12.1.1.4.1. Internal Radiation Therapy
      12.1.1.4.2. External Radiation Therapy
  12.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.2.1. Local Sarcoma
    12.1.2.2. Regional Sarcoma
    12.1.2.3. Metastatic Sarcoma
  12.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.3.1. Hospital Pharmacies
    12.1.3.2. Retail Pharmacies
    12.1.3.3. Long-Term Care Centers
  12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.4.1. Brazil
    12.1.4.2. Mexico
    12.1.4.3. Argentina
    12.1.4.4. Venezuela
    12.1.4.5. Rest of Latin America
  12.1.5. Latin America Soft Tissue Sarcoma Treatment Market - Opportunity Analysis Index - By Treatment Type, By Disease Type, By Distribution Channel, and Country, 2017 – 2023
  12.1.6. Latin America Soft Tissue Sarcoma Treatment Market Dynamics – Trends

13. MIDDLE EAST & AFRICA SOFT TISSUE SARCOMA TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  13.1.1. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.1.1. Targeted Therapy
    13.1.1.2. Chemotherapy
    13.1.1.3. Anti-angiogenesis drugs
    13.1.1.4. Radiation Therapy
      13.1.1.4.1. Internal Radiation Therapy
      13.1.1.4.2. External Radiation Therapy
  13.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.2.1. Local Sarcoma
    13.1.2.2. Regional Sarcoma
    13.1.2.3. Metastatic Sarcoma
  13.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.3.1. Hospital Pharmacies
    13.1.3.2. Retail Pharmacies
    13.1.3.3. Long-Term Care Centers
  13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.4.1. Gulf Cooperation Council (GCC) Countries
    13.1.4.2. Israel
    13.1.4.3. South Africa
    13.1.4.4. Rest of MEA
  13.1.5. MEA Soft Tissue Sarcoma Treatment Market - Opportunity Analysis Index - By Treatment Type, By Disease Type, By Distribution Channel, and Country, 2017 – 2023
  13.1.6. MEA Soft Tissue Sarcoma Treatment Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Treatment & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  14.2.1. GlaxoSmithKline plc (U.K.)
  14.2.2. Eli Lilly and Company (U.S.)
  14.2.3. Pfizer, Inc. (U.S.)
  14.2.4. Bristol-Myers Squibb (U.S.)
  14.2.5. F. Hoffmann-La Roche AG (Switzerland)
  14.2.6. Johnson & Johnson Services, Inc. (U.S.)
  14.2.7. Teva Pharmaceutical Industries Ltd (Israel)
  14.2.8. Celgene Corporation (U.S.)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS